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Allogeneic hematopoietic stem cell transplantation (HCT) is a common procedure with a good track 
record for treatment of leukemia and other blood cancers. Stem cells are taken from a donor with 
closely matching tissue type (e.g. a sibling or parent) and administered to the patient, and if the 
transplant engrafts in the recipient's bone marrow the healthy cells will soon start to produce immune 
cells from the donor stem cells. Any malignant cells that linger after pre-transplant treatment can 
thus be killed off by the new immune cells, in a process that is referred to as the graft-versus-
leukemia (GVL) effect. This is a recognized benefit of allogeneic transplants, but there are 
unfortunately disadvantages as well. The patient's healthy cells can also be attacked, which is called 
graft-versus-host disease (GVHD), a complication that can range from mild to life-threatening. 
In a recent publication in Blood, Drs. Mario Marcondes, David Hockenbery and Joachim Deeg from 
Fred Hutch's Clinical Research Division presented a new strategy to prevent acute GVHD, showing 
that a well-tolerated treatment used for α-1-antitrypsin (AAT) deficiency-related emphysema 
provided a doubly positive effect when administered to stem cell donors for HCT. AAT is a type of 
protein called serine protease inhibitor that affects a number of functions, including cell signaling, 
metabolic reactions within the cells, and cell-mediated immunity. Indications that AAT exposure of 
donor cells could lower the incidence of GVHD had been previously reported, but concerns were 
raised that the desired anti-cancer effect could be negatively affected in parallel. 
The Fred Hutch investigators showed first, in retrospective analyses on plasma samples from 111 
allogeneic transplant donors and their recipients, an inverse relationship between donor AAT levels 
and the development of GVHD in the transplanted patients. The mechanism was presumably 
mediated by the AAT-exposed donor cells; therefore, further studies were executed in mouse 
models. Transplants were performed after AAT treatment of donors and/or recipients with varying 
levels of histocompatibility antigen mismatch, showing that AAT exposure was associated with 
superior outcome; particularly beneficial results were observed after treatment of both donors and 
recipients. 
The impact on the GVL effect was examined in mice carrying a lymphoma that received allogeneic 
transplants from AAT-treated donors, and the outcome was unexpectedly positive. "The experiments 
suggest that AAT exerts potent GVHD protection while maintaining or enhancing GVL activity," said 
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Dr. Marcondes. Tumors grew significantly less compared with controls, and AAT exposure of donors 
increased the survival of the graft recipients. 
Exactly how AAT modifies the immune cells is not clear, but flow cytometric data showed that AAT 
treatment of healthy donors promoted expansion of dendritic cells, regulatory T cells and natural 
killer cells, while decreasing pro-inflammatory and enhancing anti-inflammatory cell-signaling 
proteins. Donor dendritic cells seemed particularly important for decreasing the incidence of GVHD, 
whereas the enhanced anti-tumor activity was associated with the observed increase in natural killer 
cells, combined with upregulation of their activating receptor NKG2D. In fact, evidence points 
towards NKG2D-dependent activities being imperative for the GVL effect; activities that are 
apparently increasing with AAT exposure. One explanation for this could be intensified cellular 
production of so called reactive oxygen species, which enhance the NKG2D expression. The 
investigators hypothesized that treatment with AAT might affect these mechanisms, and tested their 
theory through metabolic flux analysis. Marrow and spleen cells from exposed donors indicated a 
change in cell-type specific metabolism, with increased oxygen consumption rates in dendritic cells, 
regulatory T cells and natural killer cells, but not in cytotoxic T lymphocytes (CD4+ and CD8+). This 
pattern of effects is similar to previously documented results leading to protective immunity and 
prolonged graft survival in mice. 
Ultimately, these results indicate that there is great promise in α-1-antitrypsin for treatment, and 
possibly prevention, of acute GVHD after allogeneic HCT. In fact, a clinical phase I/II study using 
AAT for the treatment of GHVD is already underway. AAT has been used for decades and is 
"extremely well tolerated", according to Dr. Marcondes. "A short course for donors does not appear 
to be unrealistic, associated with the published data suggesting the development of transplant 
tolerance in bone marrow transplant recipients." 
That's two points for science, nil for cancer. 
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Effect of α-1-antitrypsin (AAT) on oxygen 
consumption: Ex-vivo oxygen consumption rate 
(OCR) in CD8+, NK1.1+, and CD4+ CD4+CD25+ 
FoxP3+ cells from stem cell donors treated with 
AAT or with albumin (control). 
 
 
